{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:32:19Z","timestamp":1790346739561,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.it.2020.04.004","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T17:25:31Z","timestamp":1588613131000},"page":"493-511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Opportunities for Small Molecules in Cancer Immunotherapy"],"prefix":"10.1016","volume":"41","author":[{"given":"Sabina Y.","family":"van der Zanden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien J.","family":"Luimstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Neefjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannie","family":"Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huib","family":"Ovaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2020.04.004_bb0005","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.04.004_bb0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.it.2020.04.004_bb0015","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.it.2020.04.004_bb0020","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.it.2018.09.004","article-title":"Adoptive T cell therapy: new avenues leading to safe targets and powerful allies","volume":"39","author":"Hammerl","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.it.2020.04.004_bb0025","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2020.04.004_bb0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/17425255.2016.1120287","article-title":"New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors","volume":"12","author":"Ciccarese","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.it.2020.04.004_bb0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2020.04.004_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2020.04.004_bb0045","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.it.2020.04.004_bb0050","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2020.04.004_bb0055","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/jcph.990","article-title":"Clinical pharmacology considerations for the development of immune checkpoint inhibitors","volume":"57","author":"Sheng","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.it.2020.04.004_bb0060","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/jcb.25782","article-title":"Therapeutic potential of small molecule inhibitors","volume":"118","author":"Khera","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.it.2020.04.004_bb0065","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.it.2020.04.004_bb0070","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2020.04.004_bb0075","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI23373","article-title":"Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909","volume":"115","author":"Speiser","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2020.04.004_bb0080","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.it.2020.04.004_bb0085","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1021\/acs.jmedchem.7b00293","article-title":"Small-molecule inhibitors of the programmed cell death-1\/programmed death-ligand 1 (PD-1\/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1","volume":"60","author":"Guzik","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0090","doi-asserted-by":"crossref","first-page":"30323","DOI":"10.18632\/oncotarget.8730","article-title":"Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)","volume":"7","author":"Zak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2020.04.004_bb0095","doi-asserted-by":"crossref","first-page":"12392","DOI":"10.1038\/s41598-019-48826-6","article-title":"Comprehensive in vitro characterization of PD-L1 small molecule inhibitors","volume":"9","author":"Ganesan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.it.2020.04.004_bb0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/med.21530","article-title":"Immunomodulators targeting the PD-1\/PD-L1 protein-protein interaction: from antibodies to small molecules","volume":"39","author":"Yang","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.it.2020.04.004_bb0105","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.aad1253","article-title":"Immunogenicity of somatic mutations in human gastrointestinal cancers","volume":"350","author":"Tran","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.it.2020.04.004_bb0110","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.04.004_bb0115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.04.004_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1526250","article-title":"Trial watch: toll-like receptor agonists in cancer immunotherapy","volume":"7","author":"Smith","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2020.04.004_bb0125","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.1012501","article-title":"TLR agonists: our best frenemy in cancer immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.it.2020.04.004_bb0130","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/cb500079s","article-title":"Directing the immune system with chemical compounds","volume":"9","author":"Mancini","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.it.2020.04.004_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148764","article-title":"Coordinated activation of toll-like receptor8 (TLR8) and NLRP3 by the TLR8 agonist, VTX-2337, ignites tumoricidal natural killer cell activity","volume":"11","author":"Dietsch","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.it.2020.04.004_bb0140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1078-0432.CCR-17-0357","article-title":"Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals","volume":"24","author":"Shayan","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2020.04.004_bb0145","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jamaoncol.2018.1888","article-title":"Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the Active8 randomized clinical trial","volume":"4","author":"Ferris","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.it.2020.04.004_bb0150","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1021\/acs.jmedchem.7b00419","article-title":"Discovery of small molecules as multi-toll-like receptor agonists with proinflammatory and anticancer activities","volume":"60","author":"Zhang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejmech.2017.12.026","article-title":"Targeting pattern-recognition receptors to discover new small molecule immune modulators","volume":"144","author":"Zhu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0160","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.it.2020.04.004_bb0165","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nchembio.1661","article-title":"Hydrolysis of 2\u20323\u2032-cGAMP by ENPP1 and design of nonhydrolyzable analogs","volume":"10","author":"Li","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.it.2020.04.004_bb0170","doi-asserted-by":"crossref","first-page":"10080","DOI":"10.1021\/jm501434y","article-title":"Imidazopyridine- and purine-thioacetamide derivatives: potent inhibitors of nucleotide pyrophosphatase\/phosphodiesterase 1 (NPP1)","volume":"57","author":"Chang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0175","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1021\/acs.jmedchem.7b01906","article-title":"Highly selective and potent ectonucleotide pyrophosphatase-1 (NPP1) inhibitors based on uridine 5\u2032-Palpha,alpha-dithiophosphate analogues","volume":"61","author":"Zelikman","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0180","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.it.2020.04.004_bb0185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-018-0629-6","article-title":"Nuclear cGAS suppresses DNA repair and promotes tumorigenesis","volume":"563","author":"Liu","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.04.004_bb0190","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-15-1456","article-title":"STING promotes the growth of tumors characterized by low antigenicity via IDO activation","volume":"76","author":"Lemos","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2020.04.004_bb0195","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1523097","article-title":"Priming antitumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells","volume":"8","author":"Krombach","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2020.04.004_bb0200","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2020.04.004_bb0205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.it.2020.04.004_bb0210","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1158\/0008-5472.CAN-16-0881","article-title":"Tumor eradication by cisplatin is sustained by CD80\/86-mediated costimulation of CD8+ T cells","volume":"76","author":"Beyranvand Nejad","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2020.04.004_bb0215","article-title":"Pembrolizumab plus chemotherapy in lung cancer","volume":"379","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2020.04.004_bb0220","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2020.04.004_bb0225","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2020.04.004_bb0230","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2020.04.004_bb0235","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41416-018-0076-z","article-title":"Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma","volume":"118","author":"Orecchioni","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.it.2020.04.004_bb0240","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3892\/mmr.2017.6908","article-title":"Chemotherapy oxaliplatin sensitizes prostate cancer to immune checkpoint blockade therapies via stimulating tumor immunogenicity","volume":"16","author":"Zhou","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.it.2020.04.004_bb0245","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2020.04.004_bb0250","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2020.04.004_bb0255","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2020.04.004_bb0260","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.it.2020.04.004_bb0265","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2020.04.004_bb0270","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.it.2020.04.004_bb0275","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.it.2020.04.004_bb0280","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/bs.ircmb.2017.07.004","article-title":"Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer","volume":"336","author":"Prendergast","year":"2018","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.it.2020.04.004_bb0285","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","article-title":"Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2020.04.004_bb0290","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.18632\/oncotarget.2357","article-title":"A first in man Phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors","volume":"5","author":"Soliman","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2020.04.004_bb0295","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a Phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.it.2020.04.004_bb0300","doi-asserted-by":"crossref","first-page":"CT177","DOI":"10.1158\/1538-7445.AM2018-CT177","article-title":"Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I\/II ECHO-203 study","volume":"78","author":"Aung Naing","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2020.04.004_bb0305","doi-asserted-by":"crossref","first-page":"OF5","DOI":"10.1158\/2159-8290.CD-ND2018-007","article-title":"Companies scaling back IDO1 inhibitor trials","volume":"8","author":"American Association for Cancer Research","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.it.2020.04.004_bb0310","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.04.004_bb0315","doi-asserted-by":"crossref","first-page":"21771","DOI":"10.18632\/oncotarget.4846","article-title":"IDO-GCN2 and autophagy in inflammation","volume":"6","author":"McGaha","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2020.04.004_bb0320","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1021\/acsmedchemlett.9b00400","article-title":"Identification of novel, potent, and orally available GCN2 inhibitors with type I half binding mode","volume":"10","author":"Fujimoto","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.it.2020.04.004_bb0325","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/2326-6066.CIR-16-0400","article-title":"Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance","volume":"5","author":"Hennequart","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.it.2020.04.004_bb0330","doi-asserted-by":"crossref","first-page":"2048731","DOI":"10.1155\/2016\/2048731","article-title":"Cyclooxygenase-2: a role in cancer stem cell survival and repopulation of cancer cells during therapy","volume":"2016","author":"Pang","year":"2016","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.it.2020.04.004_bb0335","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cmdc.201800685","article-title":"Carboranyl analogues of celecoxib with potent cytostatic activity against human melanoma and colon cancer cell lines","volume":"14","author":"Buzharevski","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.it.2020.04.004_bb0340","first-page":"9010","article-title":"Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.it.2020.04.004_bb0345","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/jpet.118.254359","article-title":"Inhibition of COX-2 and EGFR by melafolone improves anti-PD-1 therapy through vascular normalization and PD-L1 downregulation in lung cancer","volume":"368","author":"Tang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.it.2020.04.004_bb0350","first-page":"1203","article-title":"Prostaglandin EP2 receptor: novel therapeutic target for human cancers (review)","volume":"42","author":"Sun","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.it.2020.04.004_bb0355","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/j.1476-5381.2011.01495.x","article-title":"In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist","volume":"164","author":"af Forselles","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.it.2020.04.004_bb0360","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22647","article-title":"A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis","volume":"2","author":"Ma","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2020.04.004_bb0365","doi-asserted-by":"crossref","first-page":"89802","DOI":"10.18632\/oncotarget.21155","article-title":"Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment","volume":"8","author":"Miao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2020.04.004_bb0370","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1476-5381.2009.00278.x","article-title":"Recent advances in arginine metabolism: roles and regulation of the arginases","volume":"157","author":"Morris","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.it.2020.04.004_bb0375","doi-asserted-by":"crossref","first-page":"21123","DOI":"10.1074\/jbc.M110675200","article-title":"Regulation of T cell receptor CD3zeta chain expression by L-arginine","volume":"277","author":"Rodriguez","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2020.04.004_bb0385","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd4596","article-title":"Big opportunities for small molecules in immuno-oncology","volume":"14","author":"Adams","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2020.04.004_bb0390","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1073\/pnas.0409783102","article-title":"Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination","volume":"102","author":"De Santo","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2020.04.004_bb0395","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1084\/jem.20101956","article-title":"Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells","volume":"208","author":"Molon","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2020.04.004_bb0400","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2020.04.004_bb0405","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fimmu.2012.00190","article-title":"The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway","volume":"3","author":"Ohta","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2020.04.004_bb0410","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1021\/jm800961g","article-title":"Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines","volume":"52","author":"Gillespie","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0415","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1800991","article-title":"The next generation of immunotherapy for cancer: small molecules could make big waves","volume":"202","author":"Kerr","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2020.04.004_bb0420","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1002\/anie.201707816","article-title":"Small molecules drive big improvements in immuno-oncology therapies","volume":"57","author":"Huck","year":"2018","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.it.2020.04.004_bb0425","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1021\/acschembio.5b00899","article-title":"Synthetic RORgammat agonists enhance protective immunity","volume":"11","author":"Chang","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.it.2020.04.004_bb0430","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1254854","article-title":"Synthetic RORgamma agonists regulate multiple pathways to enhance antitumor immunity","volume":"5","author":"Hu","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2020.04.004_bb0435","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.it.2020.04.004_bb0440","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cellimm.2017.10.015","article-title":"The paradox of Th17 cell functions in tumor immunity","volume":"322","author":"Asadzadeh","year":"2017","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.it.2020.04.004_bb0445","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1461303","article-title":"Th17 cell-derived IL-17A promoted tumor progression via STAT3\/NF-kappaB\/Notch1 signaling in non-small cell lung cancer","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2020.04.004_bb0450","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.18632\/oncotarget.23934","article-title":"Interleukin 17 and peripheral IL-17-expressing T cells are negatively correlated with the overall survival of head and neck cancer patients","volume":"9","author":"Lee","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2020.04.004_bb0455","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1021\/acs.jmedchem.8b00061","volume":"61","author":"Kono","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0460","doi-asserted-by":"crossref","DOI":"10.14309\/crj.2018.56","article-title":"Rapid onset of inflammatory bowel disease after receiving secukinumab infusion","volume":"5","author":"Wang","year":"2018","journal-title":"ACG Case Rep. J."},{"key":"10.1016\/j.it.2020.04.004_bb0465","doi-asserted-by":"crossref","first-page":"L846","DOI":"10.1152\/ajplung.00321.2011","article-title":"CXCR4 regulates migration of lung alveolar epithelial cells through activation of Rac1 and matrix metalloproteinase-2","volume":"302","author":"Ghosh","year":"2012","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.it.2020.04.004_bb0470","first-page":"1133","article-title":"Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1\/CXCR4 system in oral squamous cell carcinoma cells","volume":"29","author":"Onoue","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.it.2020.04.004_bb0475","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","article-title":"Targeting CXCL12\/CXCR4 axis in tumor immunotherapy","volume":"26","author":"Zhou","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027042","article-title":"Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1\/CXCR4 axis","volume":"6","author":"Kato","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.it.2020.04.004_bb0485","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.it.2020.04.004_bb0490","doi-asserted-by":"crossref","first-page":"85185","DOI":"10.18632\/oncotarget.13238","article-title":"CXCR4 antagonists suppress small cell lung cancer progression","volume":"7","author":"Taromi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2020.04.004_bb0495","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.it.2020.04.004_bb0500","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2020.04.004_bb0505","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccr.2013.10.009","article-title":"CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis","volume":"24","author":"Katoh","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2020.04.004_bb0510","doi-asserted-by":"crossref","first-page":"114554","DOI":"10.18632\/oncotarget.23020","article-title":"CXCR2(+) MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2020.04.004_bb0515","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1158\/2326-6066.CIR-13-0223","article-title":"Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates","volume":"2","author":"Zom","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.it.2020.04.004_bb0520","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/acs.bioconjchem.9b00087","article-title":"Dual synthetic peptide conjugate vaccine simultaneously triggers TLR2 and NOD2 and activates human dendritic cells","volume":"30","author":"Zom","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0525","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2020.04.004_bb0530","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bpj.2017.10.027","article-title":"Dynamic structural differences between human and mouse STING lead to differing sensitivity to DMXAA","volume":"114","author":"Shih","year":"2018","journal-title":"Biophys. J."},{"key":"10.1016\/j.it.2020.04.004_bb0535","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1039\/C8OB01798K","article-title":"Design, synthesis, and biological evaluation of C7-functionalized DMXAA derivatives as potential human-STING agonists","volume":"17","author":"Hwang","year":"2019","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0540","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.it.2020.04.004_bb0545","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41416-018-0188-5","article-title":"STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer","volume":"119","author":"Ghaffari","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.it.2020.04.004_bb0550","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2020.04.004_bb0555","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1074\/jbc.272.13.8581","article-title":"Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway","volume":"272","author":"Hogenesch","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.it.2020.04.004_bb0560","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41467-017-00530-7","article-title":"Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2\/CD39L1 in hepatocellular carcinoma","volume":"8","author":"Chiu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2020.04.004_bb0565","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.30077","article-title":"PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma","volume":"139","author":"Ruf","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.it.2020.04.004_bb0570","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1158\/1541-7786.MCR-12-0216","article-title":"Ah receptor antagonism represses head and neck tumor cell aggressive phenotype","volume":"10","author":"DiNatale","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.it.2020.04.004_bb0575","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.it.2020.04.004_bb0580","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/0008-5472.CAN-08-2470","article-title":"Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH","volume":"69","author":"Chiche","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2020.04.004_bb0585","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3892\/or.2013.2226","article-title":"Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells","volume":"29","author":"Radvak","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.it.2020.04.004_bb0590","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-10-4261","article-title":"Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors","volume":"71","author":"Lou","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2020.04.004_bb0595","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.radonc.2009.06.019","article-title":"Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model","volume":"92","author":"Dubois","year":"2009","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.it.2020.04.004_bb0600","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACS: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.it.2020.04.004_bb0605","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.it.2020.04.004_bb0610","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ddtec.2019.02.005","article-title":"Targeted protein degradation in vivo with proteolysis targeting chimeras: current status and future considerations","volume":"31","author":"Watt","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.it.2020.04.004_bb0615","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41421-018-0079-1","article-title":"A chemical approach for global protein knockdown from mice to non-human primates","volume":"5","author":"Sun","year":"2019","journal-title":"Cell Discov."},{"key":"10.1016\/j.it.2020.04.004_bb0620","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.3389\/fimmu.2018.02697","article-title":"Specific MHC-I peptides are induced using PROTACs","volume":"9","author":"Jensen","year":"2018","journal-title":"Front. Immunol."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490620300697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490620300697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:05:26Z","timestamp":1761462326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490620300697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1471490620300697"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2020.04.004","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities for Small Molecules in Cancer Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2020.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}